戻る Agenda
Session 3b: Policy Solutions to Improve Access to Biosimilars
Session Chair(s)
Tiffany Fletcher, MA
Head of Global Access Policy
Viatris, United States
Juliana Marguerite Reed, MS
Executive Director
The Biosimilars Forum, United States
The FDA has approved 36 biosimilars and 22 are currently available to patients. Biosimilars could play an essential role in the US healthcare system, in terms of expanding access to biologic therapies, providing patient and physician choice, and addressing the healthcare budget. IQVIA estimates the expanded availability of biosimilars to save $133 billion in U.S. drug costs by 2024. This session will gain perspectives from stakeholder groups on policy solutions needed today that work to increase access to biosimilars and lower healthcare costs.
Learning Objective : At the conclusion of this session, participants should be able to:
- Define patient perspectives and needs to improve access to biosimilars
- Identify policy solutions to improve access to biosimilars
- Assess and explain US employer actions to improve access to biosimilars
Speaker(s)
Speaker
Alex M Brill, MA
Matrix Global Advisors, United States
Cheif Executive Officer
Speaker
Juliana Marguerite Reed, MS
The Biosimilars Forum, United States
Executive Director
Speaker
Marta E. Wosinska, PhD
The Brookings Institution, United States
Visiting Fellow
Speaker
Jim Carey, MBA
Organon, United States
Head of US Policy and Government Relations